Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NBI-1070770 in Adults With Major Depressive Disorder
NCT06267846Phase 2Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NBI-1070770 in major depressive disorder (MDD) (4 arms), sponsored by Neurocrine Biosciences. Primary endpoint: Montgomery-Åsberg Depression Rating Scale at 5 days. Started Mar 2024; status: completed.
02
Drugs
NBI-1070770
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06267846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06267846.